Eli LillyLLY
A drugmaker whose medicines include Mounjaro and Zepbound for diabetes and weight loss, as well as treatments for cancer and Alzheimer’s disease.
Share price
Key figures, last 12 months
- Market cap
- $1.27tn at 1354.96, 6 November 2026
- Revenue growth
- +45.5% on $86.5bn of revenue
- Operating margin
- —
- Free cash flow margin
- 22.7% +7.1 pts on a year earlier
- ROIC
- —
Financial metrics
- Revenue
- $86.5bn +45.5% on a year earlier
- Net income
- $27.6bn +49.8% on a year earlier
- Earnings per share
- $30.87
- Price to earnings
- 43.9×
- Free cash flow
- $19.7bn +112% on a year earlier
- Profit turned into cash
- 71.3%
- Spending on build-out
- 12.7% +1.3 pts on a year earlier
- Cash and investments
- $4.9bn
- Total debt
- $49.5bn
- Net cash
- −$44.6bn
- Debt to equity
- 1.23×
- Shares (diluted)
- 893m −0.6% on a year earlier
Revenue by financial year
Latest filings
- Quarterly report to 30 September 202629 October 2026
- Quarterly report to 30 June 20265 August 2026
- Quarterly report to 31 March 202630 April 2026
Coming soon
Hindsight Analysis
A closer look at Eli Lilly’s finances: what the figures reveal, the risks they show, and how the company’s promises compare with its results.
Charts and live prices are delayed, from TradingView. Market values use each company’s last trade on IEX at the previous close, times the shares in issue from its filings; company figures come from SEC filings. This is information, not investment advice. Where our market data comes from
Company logos are trademarks of their owners, shown only to identify them; the files are from Wikimedia Commons.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.